What is the promise of nicotinergic compounds in schizophrenia treatment? - Test2 - elhamkhani - TriplyDB

What is the promise of nicotinergic compounds in schizophrenia treatment?

What is the promise of nicotinergic compounds in schizophrenia treatment?

http://www.wikidata.org/entity/Q38811805

about

What is the promise of nicotinergic compounds in schizophrenia treatment?

http://www.wikidata.org/entity/Q38811805

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

What is the promise of nicotinergic compounds in schizophrenia treatment?

@en

type

label

What is the promise of nicotinergic compounds in schizophrenia treatment?

@en

prefLabel

What is the promise of nicotinergic compounds in schizophrenia treatment?

@en

P1433

Q38811805-2D2C5609-FCC2-4B31-8113-042948A805F5

P1476

Q38811805-C6CD0E6E-FD0B-495E-9F86-8FE92E540779

P2093

Q38811805-0CFF9EDE-0E1B-41AE-82D7-E82898F5192F

Q38811805-3B86426C-A722-4A60-BEE8-6EAE322FD788

P2860

Q38811805-123A1158-7B5B-4611-8373-636C403C13D1

Q38811805-228E6955-8BB1-48F6-9D18-706B0E03B170

Q38811805-24E5C738-E2A6-4692-9F2E-89CDD1100D85

Q38811805-2D11523A-7015-493D-8006-D95E387A40FD

Q38811805-2E930353-3A33-43F3-87D7-3386DF04B4B5

Q38811805-605309C6-AFD2-43C9-8C45-AF2D259E7E5F

Q38811805-684B32D6-1877-470C-84B1-082F908ED6D8

Q38811805-7D3F3976-1F2A-4465-A6DF-280908C5ABCA

Q38811805-8C51FBFE-99BA-4050-88C8-686077265D7A

Q38811805-91D4ADF4-A673-43AC-AA16-4183C4D0D3E8

P31

Q38811805-3B8A617A-D3EF-43A0-89A7-FC0216240615

P356

Q38811805-19187664-3989-4FD9-80CA-AB53E9908CCF

P50

Q38811805-0D35C931-988B-4D69-8847-50E52818EDF1

P577

Q38811805-8A378685-AEE8-4042-B53C-26E720FDBFD8

P698

Q38811805-E3B7EE63-72F7-4BD8-8C4A-5CA076150ED4

P921

Q38811805-7F8277A3-4A15-4E10-963E-69D01191B079

P356

P1433

Future Medicinal Chemistry

P1476

What is the promise of nicotinergic compounds in schizophrenia treatment?

@en

P2093

F Markus Leweke

http://www.w3.org/2001/XMLSchema#string

Juliane K Mueller

http://www.w3.org/2001/XMLSchema#string

P2860

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

Nicotinic ACh receptors as therapeutic targets in CNS disorders

Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.

Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia

Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study.

A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia

Normalizing effects of EVP-6124, an α-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia.

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.

Initial phase 2 trial of a nicotinic agonist in schizophrenia.

P31

scholarly article

P356

10.4155/FMC-2016-0154

http://www.w3.org/2001/XMLSchema#string

P50

Cathrin Rohleder

P577

2016-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27739330

http://www.w3.org/2001/XMLSchema#string

P921